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Metformin Decreases the 
Incidence of Pancreatic Ductal 
Adenocarcinoma Promoted 
by Diet-induced Obesity in the 
Conditional KrasG12D Mouse 
Model
Hui-Hua Chang  1, Aune Moro1, Caroline Ei Ne Chou1, David W. Dawson2, Samuel French  2,  
Andrea I. Schmidt1,3, James Sinnett-Smith4, Fang Hao4, O. Joe Hines1, Guido Eibl  1 & 
Enrique Rozengurt4
Pancreatic ductal adenocarcinoma (PDAC) is a particularly deadly disease. Chronic conditions, including 
obesity and type-2 diabetes are risk factors, thus making PDAC amenable to preventive strategies. We 
aimed to characterize the chemo-preventive effects of metformin, a widely used anti-diabetic drug, on 
PDAC development using the KrasG12D mouse model subjected to a diet high in fats and calories (HFCD). 
LSL-KrasG12D/+;p48-Cre (KC) mice were given control diet (CD), HFCD, or HFCD with 5 mg/ml metformin 
in drinking water for 3 or 9 months. After 3 months, metformin prevented HFCD-induced weight gain, 
hepatic steatosis, depletion of intact acini, formation of advanced PanIN lesions, and stimulation 
of ERK and mTORC1 in pancreas. In addition to reversing hepatic and pancreatic histopathology, 
metformin normalized HFCD-induced hyperinsulinemia and hyperleptinemia among the 9-month 
cohort. Importantly, the HFCD-increased PDAC incidence was completely abrogated by metformin 
(p < 0.01). The obesogenic diet also induced a marked increase in the expression of TAZ in pancreas, an 
effect abrogated by metformin. In conclusion, administration of metformin improved the metabolic 
profile and eliminated the promoting effects of diet-induced obesity on PDAC formation in KC mice. 
Given the established safety profile of metformin, our findings have a strong translational potential for 
novel chemo-preventive strategies for PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is a particularly aggressive and lethal cancer with an overall 5-year 
survival rate of approximately 8%1. In the United States, 53,670 new cases are expected in 2017 and PDAC pres-
ently ranks as the fourth leading cause of cancer-related mortality1. Due to the continuing lack of effective diag-
nostic and therapeutic modalities, total PDAC deaths are estimated to become the second leading cause of cancer 
mortality before the year 20302. Research efforts have therefore increased to prevent and intercept this disease3–5. 
There is clearly an urgent need to identify novel targets and agents for prevention. Understanding the mechanisms 
of modifiable risk factors and repurposing currently used drugs will most likely guide the rapid implementation 
of new preventive strategies.
Based on epidemiological analyses, chronic conditions such as obesity and long-standing type 2 diabetes 
mellitus (T2DM) are linked with increased risk and worse outcomes of PDAC and other cancers6–9. In addition 
to the epidemiologic evidence, tumor-promoting effects of high-fat diets and diet-induced obesity have also been 
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demonstrated in animal models of PDAC10–12. Given the increasingly high prevalence of obesity and related met-
abolic syndromes including T2DM, detailed mechanistic studies targeting obesity-associated PDAC are of great 
significance in the development of novel preventive or therapeutic strategies for this deadly disease.
Metformin (1,1-dimethylbiguanide hydrochloride) is the most widely prescribed drug for treatment of T2DM 
worldwide13,14. The primary systemic effect of metformin is the lowering of blood glucose levels through reduced 
hepatic gluconeogenesis and improved insulin sensitivity by increasing glucose uptake in peripheral tissues, 
including skeletal muscles and adipose tissue. In previous studies, we demonstrated that metformin potently 
stimulates AMP–activated protein kinase (AMPK) activation in PDAC cells cultured in physiological glucose15,16 
and inhibited the mammalian target of rapamycin 1 (mTORC1) and extracellular signal-regulated kinase (ERK) 
via AMPK at low concentrations15–17. Epidemiologically, metformin administration has been linked with reduced 
incidence, recurrence and mortality of cancer in diabetic patients18–25, although a therapeutic efficacy of met-
formin is not universally seen in all studies26, especially in advanced cases of cancer. Indeed, a recent meta-analysis 
indicated that the effects of metformin depend on tumor stage, with marked improved survival in patients with 
locally advanced disease but not in patients with metastatic PDAC23. Although the anti-cancer activity of met-
formin is supported by preclinical and epidemiological studies, the mechanisms involved remain incompletely 
understood. Systemically, the insulin-lowering effects of metformin may contribute to its anti-cancer activity 
since insulin is a known mitogenic factor and hyperinsulinemia is one of the proposed mechanisms through 
which obesity promotes cancer. Our previous studies have demonstrated that metformin inhibits PDAC growth 
in vitro through disrupting the signaling crosstalk between G protein-coupled receptor (GPCR) and insulin/
insulin-like growth factor (IGF) receptor15,16,27. Further, we showed that administration of metformin (given 
i.p. or via the drinking water) inhibited the growth of PDAC cells xenografted either subcutaneously or ortho-
topically27,28. However, the efficacy and mechanisms of metformin as a preventive strategy in obesity-promoted 
PDAC are unknown.
Previously, we have reported a highly relevant animal model, in which PDAC was promoted by diet-induced 
obesity (DIO). In that study, mice that express oncogenic Kras in the pancreas (LSL-KrasG12D/+;p48-Cre: KC) 
were subjected to a diet high in fats and calories (HFCD)11,12. When compared to lean, control diet (CD)-fed 
mice, HFCD-fed animals gained substantially more weight and were characterized by metabolic disturbances, 
including hyperglycemia, hyperinsulinemia, and hyperleptinemia. Obese KC mice developed robust pancreatic 
inflammation, more advanced precancer lesions, i.e. pancreatic intraepithelial neoplasia (PanIN), and higher inci-
dence of PDAC11,12. In the present study, we used this animal model to characterize the chemo-preventive effects 
of metformin on obesity-related PDAC development. Strikingly, oral administration of metformin attenuated or 
even reversed the pathologic results of DIO in this model, including metabolic disturbances and increased PDAC 
incidence. These results suggest that metformin offers a potentially novel approach for prevention/interception 
of obesity-associated PDAC.
Results
Metformin prevents HFCD-induced weight gain, hepatic steatosis, hyperleptinemia, and hyper-
insulinemia in KC mice. To examine the effects of metformin on PDAC promoted by diet-induced obesity, 
we used a mouse model, in which an obesogenic diet markedly accelerated the development of PDAC in KC 
mice11,12. Animals were treated without or with metformin (5 mg/ml in drinking water) starting at one month 
until 3 or 9 months of age. This well-tolerated dose of metformin was determined based on previous reports to 
achieve a similar steady-state plasma concentration to that of T2DM patients29. The HFCD-fed KC mice gained 
more weight (g) than CD-fed KC mice in both females and males at 3 and 9 months. Remarkably, oral admin-
istration of metformin prevented HFCD-induced weight gain in both female and male KC mice at either 3 or 9 
months (Fig. 1a).
KC mice fed the CD showed largely unremarkable liver histology with 0–5% mixed large and small droplet 
macro-vesicular steatosis. Obese KC mice on the HFCD showed 40–50% mixed macro- and micro-vesicular ste-
atosis with ballooning hepatocytes. Impressively, KC mice fed the HFCD and treated with metformin displayed 
essentially normal liver histology with 0–5% mixed large and small droplet macro-vesicular steatosis (Fig. 1b). All 
mice showed minimal non-specific lymphocytic infiltrates with no significant neutrophilic inflammation in the 
liver. In the 3-month cohort, obese female and male KC mice displayed hyperleptinemia, which was normalized 
by metformin (Supplementary Fig. S1). After 3 months, insulin levels were slightly, but not significantly elevated 
in female and male obese KC mice (Supplementary Fig. S1). However, HFCD-fed obese 9-month-old mice devel-
oped significantly increased plasma levels of insulin and leptin, as compared with the CD-fed group (Fig. 1c and d). 
The increase in leptin and insulin showed a strongly positive correlation to weight gain (p < 0.0001). 
Administration of metformin prevented the increase in the levels of circulating insulin and leptin in obese female 
and male KC mice subjected to HFCD at 9 months (Fig. 1c and d). These results demonstrate that oral adminis-
tration of metformin reversed the histologic abnormalities in the liver and prevented the hyperinsulinemia and 
hyperleptinemia induced by the obesogenic diet in both female and male KC mice.
Metformin decreases the incidence of advanced PanIN-3 and the activity of proliferative signa-
ling in HFCD-fed, obese KC mice. Next, we examined the impact of metformin on the histologic architec-
ture of the pancreas of KC mice subjected to CD, HCFD and HFCD in conjunction with metformin. Consistent 
with our previous reports11,12, obese female or male KC mice at 3 or 9 months displayed significantly more PanIN-
3, compared to age-matched lean mice. Metformin completely prevented the formation of PanIN-3 lesions in 
the cohort sacrificed at 3 months and drastically reduced obesity-associated PanIN-3 lesions in the 9-month 
cohort (Fig. 2a). Similarly, obese female or male KC mice fed the HFCD at either 3 or 9 months showed less intact 
acini. Administration of metformin completely prevented the depletion of intact acini at 3 months and partially 
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reversed the striking decrease of intact acini at 9 months (Fig. 2b). Overall, the administration of metformin 
greatly preserved the histological architecture of the pancreas (Fig. 2c).
A major mechanism, by which metformin directly inhibits proliferation of PDAC cells in culture is via 
stimulation of AMPK15,27,30, which mediates inhibition of key pathways for PDAC cell proliferation, including 
mTORC1 and mitogen-activated protein kinase kinase (MEK)/ERK30,31. Consequently, we determined whether 
metformin increases AMPK and exerts any inhibitory effect on these pathways in the pancreas of KC mice fed the 
CD, HFCD, and HFCD with metformin, as scored by western blot analysis using specific antibodies to detect the 
phosphorylated state of these proteins in pancreatic lysates. Initially, we verified that metformin administration 
induced a marked increase (2.5-fold) in the phosphorylation of acetyl-CoA carboxylase (ACC) at Ser79 (Fig. 3a, 
quantification in Fig. 3b) a direct substrate of AMPK and a marker of intracellular AMPK activity32. These results 
indicate that metformin stimulates AMPK in the pancreas and are consistent with the possibility that metformin 
acts directly in pancreatic cells of KC mice.
Our results also show that obese KC mice displayed a marked activation of MEK (2.7-fold) and ERK (3.5-fold), 
as scored by phosphorylation of ERK and of MEK (Fig. 3a, quantification in Fig. 3b). Similarly, obese KC mice 
showed a marked increase in mTORC1 activity, as judged by the enhancement in the phosphorylation of the 
ribosomal protein S6 at Ser235/236, a direct target of p70S6 kinase (p70S6K) which in turn, is activated by mTORC1 
(Fig. 3a, quantification in Fig. 3b). A salient feature of the results shown in Fig. 3a and b is that metformin admin-
istration to HFCD-fed, obese mice at 3 months profoundly inhibited the increase in the phosphorylation of MEK, 
ERK, and S6 Ser235/236.
Figure 1. Metformin reverses weight gain, hepatic steatosis and increases in circulating insulin and leptin in 
KC mice subjected to a HFCD. (a) Weight gain (g) in female (left panel) and male (right panel) KC mice fed 
the CD, HFCD, or HFCD plus metformin at 3 or 9 months. Values are means ± s.d. *p < 0.05 vs. CD, #p < 0.05 
vs. HFCD. (b) Representative H&E staining of the liver of a KC mouse fed the HFCD (left) or HFCD plus 
metformin (right). (c and d) Plasma concentrations (pg/ml) of insulin (c) and leptin (d) in female and male 
KC mice fed the CD, HFCD, or HFCD plus metformin at 9 months. Values are means ± s.d. *p < 0.05 vs. CD, 
#p < 0.05 vs. HFCD. The number of animals used in the analyses are provided in each bar.
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In order to explore further whether metformin can act directly on pancreatic cells of mice harboring KrasG12D, 
we determined the ability of metformin to inhibit colony formation of cells isolated from KC mice and cultured 
in medium containing a physiological concentration of glucose15,16. As shown in Fig. 3c, metformin significantly 
inhibited colony formation at low concentrations in KC cells, with 50% inhibition of colony formation produced 
at ~0.2 mM.
Metformin decreases the incidence of PDAC and prevents the increase in TAZ expression in KC 
mice subjected to HFCD. Subsequently, we determined the cancer incidence in lean and obese KC mice 
subjected to CD, HFCD or HFCD with metfomin (Fig. 4). PDAC was identified in 2 of 13 mice (15%) fed the 
CD but in 7 of 12 mice (58%; 5 of 7 male and 2 of 5 female mice) subjected to HFCD (CD vs. HFCD, p = 0.04), in 
line with recent results showing that an obesogenic diet markedly increases the incidence of PDAC in KC mice11. 
A striking feature of the results presented in Fig. 4 is that only 1 out of 14 mice (7%; 1 of 8 females) treated with 
HFCD and metformin at 9 months developed PDAC (HFCD vs. HFCD + metformin, p < 0.01). The data clearly 
indicate that metformin administration dramatically reduced the incidence of advanced PanIN-3 (Fig. 2) and 
PDAC (Fig. 4) in obese, HFCD-fed KC mice.
The transcriptional co-activator WW-domain-containing Transcriptional co-Activator with PDZ-binding 
motif (TAZ), a major downstream effector of the Hippo pathway, has emerged as key oncogenic protein in 
PDAC33–35 and other cancer cells36. TAZ and its paralog Yes-associated protein (YAP), act downstream of KRAS 
Figure 2. Metformin prevents the disruption in histologic pancreatic architecture induced by a HFCD in 
KC mice. (a) Percentage (%) of PanIN-3 lesions in female (left panel) and male (right panel) KC mice fed the 
CD, HFCD, or HFCD plus metformin at 3 or 9 months. Values are means ± s.d. *p < 0.05 vs. CD, #p < 0.05 
vs. HFCD. (b) Percentage (%) of intact acini in female (left panel) and male (right panel) KC mice fed the 
CD, HFCD, or HFCD plus metformin at 3 or 9 months. Values are means ± s.d. *p < 0.05 vs. CD, #p < 0.05 vs. 
HFCD. (c) Representative H&E staining of the pancreas of a KC mouse fed the HFCD (left) or HFCD plus 
metformin (right). The number of animals used in the analyses are provided in each bar.
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signaling in PDAC33,34. TAZ differs from YAP, the other major effector of the Hippo pathway, in its protein 
stability. TAZ is an unstable protein that contains N-terminal and C-terminal phosphodegrons37,38 leading to 
proteolytic degradation and thus, the level of TAZ protein expression is a marker of its activity in the cell39. 
Consequently, we determined whether the expression of TAZ increases in the pancreas of KC mice subjected to 
HFCD and whether metformin administration has any effect on the levels of this oncogenic protein. Western blot 
analysis demonstrated a marked increase in the levels of TAZ protein in pancreatic extracts of KC mice subjected 
to HFCD at either 3 or 9 months, as compared with lean KC mice on CD (Fig. 5). A noticeable aspect of the data 
is that the administration of metformin, under conditions that prevented the formation of PanIN-3 lesions and 
depletion of intact acini (Fig. 2) and PDAC development (Fig. 4), virtually abrogated the increase in the expres-
sion of TAZ protein.
Discussion
It is of great interest to explore novel interventional strategies for PDAC, an almost universally lethal disease 
with few efficacious treatment modalities. Given the high prevalence of obesity and its role in promoting cancer 
development, targeting the interplay of obesity, diabetes, and PDAC will shed new light on treatment options. In 
particular, repurposing metformin for the prevention of obesity-associated PDAC has great clinical relevance. 
Figure 3. Metformin decreases the activity of proliferative signaling in HFCD-fed KC mice. (a) Western 
blotting in pancreatic lysates from KC mice fed CD, HFCD or HFCD plus metformin sacrificed at 3 months. 
Shown are representative immunoblots of p-ACC Ser79, p-MEK1/2 Ser217/221, p-S6 Ser235/236, p-ERK1/2 Thr202 
and Tyr204, β-Actin and GAPDH were used as loading controls. Each lane represents an individual mouse; 
two mice per group are shown. For p-ACC Ser79 and the corresponding GAPDH loading control a cropped 
image is shown. Irrelevant lanes were removed (indicated by a vertical line) from the acquired digital images, 
and flanking lanes were juxtaposed using Adobe Photoshop. Full-length blots are presented in Supplementary 
Information. (b) Graphs show the quantification of immunoblots as ratio of phosphorylated protein to 
GAPDH for p-ACC Ser79 or β-Actin for p-MEK1/2 Ser217/221, p-S6 Ser235/236 and p-ERK1/2 Thr202 and Tyr204. 
Values are means ± s.e.m. n = 6. P values *<0.05, **<0.001 vs. CD; #<0.05, ##<0.01 vs. HFCD. Densitometry 
was performed using Multi Gauge V3.0 software (Fujifilm Life Sciences) and statistical analyses conducted 
via SigmaPlot software. (c) Cell colony formation was performed as described in the Materials and Methods 
section. KC cells were incubated for 4 days without or with metformin at the indicated concentrations. The bars 
represent the number of colonies (mean ± s.e.m.; n = 3 dishes per condition). T-test p values comparing the 
indicated two groups to the untreated control (0) were **<0.001.
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In the present study, we demonstrate that orally administered metformin significantly prevents the development 
of PDAC in a relevant mouse model characterized by obesity and insulin resistance.
In our animal model, the HFCD led to a marked increase of weight gain and elevated plasma leptin levels evi-
dent by 3 months of age, and significantly higher plasma insulin levels at a later time point (9 months of age). The 
observed hyperinsulinemia and hyperleptinemia were highly correlated with HFCD-induced weight gain, reca-
pitulating conditions in most overweight or obese individuals who have at least some degree of insulin and leptin 
resistance. Importantly, the HFCD-induced weight gain and metabolic disturbance were completely prevented by 
Figure 4. Metformin reverses the increase in PDAC incidence in HFCD-fed KC mice. (a) PDAC incidence 
(%) in KC mice fed the CD, HFCD, or HFCD with metformin and sacrificed at 9 months of age. Values in bars 
denote numbers of mice without or with PDAC. (b) Representative H&E images of PDAC (left and right panel) 
in KC mice fed the HFCD and a liver metastasis (center) in a KC mouse fed the HFCD.
Figure 5. Metformin prevents the increase in the expression of TAZ protein in pancreatic lysates of KC mice 
subjected to a HFCD. Western blotting in pancreatic lysates from KC mice fed the CD or HFCD or HFCD plus 
metformin (HFCD + Met) at 3 months (a) and 9 months (b). Shown are representative immunoblots of TAZ 
and GAPDH, used as loading control. Each lane represents an individual mouse. Bar Graphs show the ratio of 
TAZ protein to GAPDH, mean ± s.e.m., n = 6. Densitometry was performed using Multi Gauge V3.0 software 
(Fujifilm Life Sciences) and statistical analyses conducted via SigmaPlot software. Uncropped full-length blots 
are presented in Supplementary Information.
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the intake of metformin, which is consistent with its documented effects40. These results also indicate that biolog-
ically effective concentrations of metformin were achieved in those mice receiving the drug.
Another prominent feature of the HFCD-fed mice is hepatic steatosis. This condition is within the spectrum of 
non-alcoholic fatty liver disease (NAFLD) that affects 60–95% of obese population, and is strongly associated with 
insulin resistance41. Insulin resistance has been proposed as a central mechanism leading to hepatic steatosis42, 
thereby making insulin-sensitizing drugs such as metformin a potential therapeutic option for this liver disease. 
Our study shows that metformin ameliorated hepatic steatosis associated with HFCD-induced obesity, which is 
consistent with other reports using high-fat diet-fed experimental animals43–45. However, a meta-analysis, which 
included only a few randomized trials with small patient numbers, concluded that 4–12 months of metformin 
use has no significant beneficial effect on improving liver histology in NAFLD patients46. Our results may support 
future larger randomized, placebo-controlled trials (RCTs) evaluating higher dose, long-term efficacy, and early 
intervention in the disease course, as well as identifying the most susceptible population, to achieve the maximal 
beneficial impact of metformin.
Despite accumulating epidemiological evidence indicating the anti-cancer effects of metformin, it remains 
controversial whether metformin use is associated with improved PDAC outcome47. In particular, metformin 
seems to offer no significant survival benefits in the late stage disease, based on two recently published RCTs 
examining the effect of metformin on overall survival in patients with advanced PDAC23,48,49. However, a recent 
multicenter, double-blind RCT investigated the chemo-preventive efficacy of metformin in colorectal cancer and 
found that low-dose metformin for one year significantly reduced the incidence of recurrent polyps and adeno-
mas50, implicating that the use of metformin in cancers is likely more applicable in preventive rather than ther-
apeutic settings. Unlike colorectal cancer, evidence for the chemo-preventive property of metformin in PDAC 
has not been demonstrated by randomized trials and is largely derived from normal weight/non-diabetic animal 
models51–53, where metformin might be less effective54,55.
To the best of our knowledge, the anti-neoplastic effects of metformin on PDAC in the context of diet-induced 
obesity with insulin resistance has not yet been reported in genetically engineered animal models of PDAC. In 
line with previous studies using high-fat diet-fed, carcinogen-induced56 and engrafted55,57 PDAC models, our 
results show that metformin effectively prevents the progression of advanced PanINs and the development of 
KRAS-driven PDAC promoted by diet-induced obesity.
The anti-cancer property of metformin can be mediated by direct, indirect (systemic) or combined 
effects of the drug, and it has been a major challenge to differentiate these mechanisms in vivo. Interestingly, 
HFCD-induced histological changes, including PanIN-3 formation and acini depletion, were completely restored 
by metformin at 3 months, when its insulin-lowering effect was not significant. This observation suggests that, at 
least in the model used in this study, the mechanism through which metformin exerts its anti-neoplastic activity 
involves more direct effects on transformed cells. In line with this possibility, we found that metformin pro-
duced a marked increase in AMPK activity within the pancreas, as scored by phosphorylation of ACC at Ser79, 
a site directly phosphorylated by AMPK and consequently a marker of the activity of the enzyme in the cell32. 
Furthermore, metformin also inhibited the activation of other pathways targeted by AMPK, including mTORC1 
and MEK/ERK, in pancreatic lysates of KC mice receiving an obesogenic diet. Collectively, these results are con-
sistent with the notion that the cancer preventive effects of metformin are mediated, at least in part, through 
direct effects on pancreatic epithelial cells harboring KrasG12D.
The transcriptional co-activators YAP and TAZ, two major downstream effectors of the Hippo pathway 
implicated in driving multiple cancers36, have emerged as key oncogenic proteins in PDAC that act downstream 
of KRAS signaling33,34. There are several possible pathways, by which KRAS regulates YAP/TAZ localization 
and activity, including Rho, PI3K, PKD and GPCRs58. TAZ differs from YAP, the other major effector of the 
Hippo pathway, in its protein stability. Accordingly, the level of these oncogenic proteins often are differentially 
expressed in different cancer cell types59. TAZ is an unstable protein that contains N-terminal and C-terminal 
phosphodegrons. The phosphorylation of the two phosphodegrons mediated by large tumor suppressor kinase 
1/2 (LATS1/2) and nutrient-sensitive kinases, including phosphoinositide 3-kinase (PI3K)/ protein kinase B 
(AKT)/ glycogen synthase kinase 3 (GSK3)37,38 promotes proteasome-mediated degradation and thereby regu-
lates TAZ protein expression and activity in the cell39. However, it was not known whether an obesogenic diet that 
promotes PDAC development in KC mice has any effect on the level of pancreatic TAZ. In this study, we found a 
marked increase in the level of TAZ protein in pancreatic extracts of KC mice subjected to HFCD. Shown for the 
first time, the administration of metformin, under conditions that prevented the formation of PanIN-3 lesions, 
depletion of intact acini and PDAC development, virtually abrogated the increase in the expression of TAZ pro-
tein. It is plausible that the suppressing effects of metformin on TAZ expression are mediated by the inhibitory 
effects of metformin on obesogenic signaling or by direct inhibitory actions of AMPK, which is activated by 
metformin, on YAP/TAZ58. Given recent reports implicating TAZ in PDAC development33–35, it is possible that 
HFCD-induced TAZ protein accumulation is one of the mechanisms by which the obesogenic diet promotes and 
metformin opposes PDAC development in KC mice.
In conclusion, our results support the notion that metformin, the most widely prescribed drug for treatment 
of T2DM worldwide, could be chemo-preventive for PDAC particularly in the obese population with new-onset 
diabetes mellitus that is at higher risk of developing PDAC.
Methods
Experimental animals. Offspring of LSL-KrasG12D/+ and p48-Cre+/− mice60 were randomly allocated to a 
control diet (CD), a high fat, high calorie diet (HFCD), or HFCD with metformin in the reverse osmosis drink-
ing water (5 mg/ml) at one month of age. All mice had free access to the diet. Mice fed the HFCD has free access 
to either regular drinking water or drinking water (reverse osmosis) supplemented with metformin (5 mg/ml). 
Water supplemented with metformin was made fresh and replenished twice weekly. Body weights were measured 
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weekly and the general health and behavior of animals were assessed daily. At 3 and 9 months of age cohorts of 
mice (male and female) were sacrificed and tissues harvested. All studies involving animals were reviewed and 
approved by the Chancellor’s Animal Research Committee of the University of California, Los Angeles in accord-
ance with the NIH Guide for the Care and Use of Laboratory Animals (protocol number: 2011-118).
Genotyping analysis. LSL-KRASG12D and Cre alleles were detected prior to randomizing to the experimen-
tal diets by PCR analysis of genomic DNA, as described61. Mutant (KC) mice expressed both LSL-KRASG12D and 
Cre alleles, and animals carrying neither allele were labeled wildtype (WT).
Experimental diets. Diets were prepared by Dyets, Inc. (Bethlehem, PA). At one month of age mice were 
randomized to receive either the CD, HFCD, or HFCD with 5 mg/ml metformin (Sigma-Aldrich, St. Louis, MO) 
in the drinking water. A detailed composition of the diets was described previously12. Briefly, while the CD con-
tained 12% calories from fat, 40% of calories in the HFCD stem from fat (corn oil-based). All diets were stored at 
−20 °C (long-term) or 4 °C (short-term) in sealed containers and prepared under low light conditions. The diets 
were replaced on a weekly basis and the metformin containing water was refreshed twice a week.
Metabolic panel. At the end of the study, blood was collected by cardiac puncture. Plasma was obtained by 
centrifugation (5,000 rpm for 10 minutes at room temperature) and stored at −80 °C. Levels of insulin and leptin 
were quantified using the MILLIPLEX MAP Mouse Adipokine Magnetic Bead Panel - Endocrine Multiplex Assay 
(EMD Millipore, Billerica, MA) according to the manufacturer’s guidelines. Cholesterol, glucose, and triglycer-
ides were measured by the UCLA Division of Laboratory Animal Medicine.
Pancreas and liver histology. Hematoxylin and eosin (H&E) stained tissue sections of the pancreas and 
liver, fixed in formalin and embedded in paraffin, were assessed by gastrointestinal pathologists blinded to the 
experimental groups. The presence and stage of murine PanINs and PDACs were analyzed according to previ-
ously published criteria62,63. For each animal approximately 100 pancreatic ducts (tail of the pancreas) were quan-
tified and the proportion of murine PanIN-3 to the overall number of pancreatic ducts was recorded.
Colony Formation. KC cells were grown in Dulbecco Modified Eagle Medium (DMEM) with 2 mmol/L 
glutamine, 1 mmol/L Na-pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin and 5% fetal bovine serum 
(FBS) at 37 °C in a humidified atmosphere containing 10% CO2. For cell colony formation, 500 KC cells were 
plated into 35-mm tissue culture dishes in DMEM containing 5% FBS. After 24 hours of incubation at 37 °C, 
cultures were switched to DMEM containing 1% FBS either in the absence or presence of metformin. A colony 
consisted of at least 50 cells. Cell colony numbers from three dishes per condition were determined after 4 days 
of incubation.
Western blotting. Tissue samples were homogenized in G-Lysis (Cytoskeleton, Inc., Denver, CO) buffer 
and the resulting homogenates were centrifuged at 18,000 × g. The protein concentration of the supernatants 
was determined with the bicinchoninic acid (BCA) Protein Assay kit (Thermo Fisher Scientific, Waltham, MA). 
An equal volume of 4× sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) sample buffer 
(40 mM Tris/HCl, pH 6.8, 6% SDS, 4 mM ethylenediaminetetraacetic acid (EDTA), 8% 2-mercaptoethanol, 20% 
glycerol) was added to each supernatant and boiled for 10 min, followed by SDS-PAGE on 4–15% gradient gels 
and transfer to Immobilon-P membranes (EMD Millipore). Western blots were performed on membranes incu-
bated overnight with the specified antibodies in PBS containing 0.1% Tween-20. The immunoreactive bands were 
detected with enhanced chemiluminescence (ECL) reagents (GE Healthcare Bio-Sciences Corp, Piscataway, NJ). 
The membranes were imaged using a chemiluminescence image analyzer LAS-4000 mini (Fujifilm Life Sciences, 
Tokyo, Japan), and the intensity of signals normalized to the loading controls was quantified with Multi Gauge 
V3.0 software (Fujifilm Life Sciences). The antibodies used were: polyclonal antibodies to phospho acetyl-CoA 
carboxylase Ser79, phospho MEK1/2 Ser217/221, phospho S6 Ser235/236, and a monoclonal antibody to phospho 
ERK1/2 Thr202 and Tyr204, and YAP/TAZ, all obtained from Cell Signaling Technology (Danvers, MA). Equal 
loading of the gels was verified using monoclonal antibodies to β-Actin and or glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) (Santa Cruz Biotechnology, Santa Cruz, CA).
Statistical analysis. Values are presented as mean ± standard deviation (s.d.) or standard error of mean 
(s.e.m.). In general, one-way (or two-way) ANOVA and two-tailed Student’s t-tests assuming unequal variances 
were performed to assess statistical significance. Significance was considered at a p-value less than 0.05 and indi-
cated by an asterisk (*). For the comparison of cancer incidences, Fisher’s exact test was performed.
Data availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information file).
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